Avidity Biosciences Inc
RNAM
주식 순위
#2068
Avidity Biosciences, Inc. is at the forefront of developing a novel class of... Avidity Biosciences, Inc. is at the forefront of developing a novel class of oligonucleotide-based therapies, known as Antibody Oligonucleotide Conjugates (AOCs). Utilizing its proprietary AOC platform, the company engineers treatments that strategically merge the targeted delivery capabilities of monoclonal antibodies with the precise action of oligonucleotide-based therapeutics. This innovative method aims to reach cell and tissue types previously inaccessible to treatment, thereby more effectively addressing the fundamental genetic causes of various diseases. The company was established on November 13, 2012, by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick, and its main office is located in San Diego, California.
주가
$71.34
마지막 동기화: 2026-03-03
시가총액
$9.84B
변동 (1일)
0.00%
변동 (1년)
-
국가
US
거래 Avidity Biosciences Inc (RNAM)
카테고리
Healthcare
Avidity Biosciences Inc (RNAM)의 P/S 비율
October 2026 기준 P/S 비율 TTM: 655.07
Avidity Biosciences Inc의 최신 재무 보고서와 주가에 따르면 현재 P/S 비율(TTM)은 655.07입니다. 2024년 말 기준 P/S 비율은 743.81였습니다.
Avidity Biosciences Inc의 P/S 비율 기록 (2018 ~ 2026)
매년 말 P/S 비율
| 연도 | P/S 비율 | 변화 |
|---|---|---|
| 2026 (TTM) | 655.07 | 22.82% |
| 2025 | 533.36 | -28.29% |
| 2024 | 743.81 | 34.08% |
| 2023 | 554.77 | 35.05% |
| 2022 | 410.78 | 27.30% |
| 2021 | 322.68 | 39.17% |
| 2020 | 231.86 | -80.28% |
| 2019 | 1.18K | -83.65% |
| 2018 | 7.19K | 0.00% |
유사 기업 또는 경쟁사의 P/S 비율
| 회사 | P/S 비율 | P/S 비율 차이 | 국가 |
|---|---|---|---|
| 10.02 | -98.47% |
US
|
|
| 41.70 | -93.63% |
US
|
|
| 4.19 | -99.36% |
AU
|
|
| 4.52 | -99.31% |
BE
|
|
| 10.44 | -98.41% |
NL
|
